MolDX: DecisionDx-UM (Uveal Melanoma)

Summary of Evidence Analysis of Evidence General Information Associated Information Sources of Information Bibliography Revision History Information Associated Documents Attachments Related Local Coverage Documents Related National Coverage Documents Public Versions Keywords Local Coverage Determination (LCD) MolDX: DecisionDx-UM (Uveal Melanoma) L37033 Expand All | Collapse All  Email Document  Download  Add to basket Contractor Information Contractor Name Contract Type Contract Number Jurisdiction States LCD Information Document Information LCD ID L37033 LCD Title MolDX: DecisionDx-UM (Uveal Melanoma) Proposed LCD in Comment Period N/A Source Proposed LCD DL37033 Original Effective Date For services performed on or after 07/10/2017 Revision Effective Date For services performed on or after 06/30/2022 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date 05/25/2017 Notice Period End Date 07/09/2017 CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components

This Medicare contractor will provide limited coverage for the DecisionDx-UM (Castle Bioscience, Inc.) test for the management of newly diagnosed uveal melanoma. This test is intended for the determination of metastatic risk, and to guide surveillance and referral to medical oncology (preferably an oncologist with expertise in melanoma) in patients who have a confirmed diagnosis of uveal melanoma (UM) and no evidence of metastatic disease.